Redeye states the report aligned with its estimates, and Gasporox has now produced positive EBITDA s...
The share price has been relatively weak despite net sales and operating profit looking set to impro...
Q1 report due Thursday, 25 April at 07:00 CET '24e-'26e EBITA up 4-5%; 6% CAGR '23-'26e 11-9x EBITA ...
Redeye comments on the announcement of a SEK120m rights issue of units.
Q1e a seasonally small quarter Divests loss-making business, EBITA margin +0.
Negativ organisk tillväxt… Den organiska tillväxten var -9% i Q1.
Fastighetsbolaget Trianon redovisade hyresintäkter om 732,8 miljoner kronor under 2023.
Redeye ser positivt på helgens nyhet att Eisai och BioArctic ingått ett forskningsutvärderingsavtal ...
Redeye anticipates that Physitrack will resume its sequential growth trajectory in Q1 2024, albeit w...
Redeye comments on Embracer’s announcement that it intends to split-up its business into three liste...
Redeye comments on Nepa ahead of its Q1 results (due 7 May).
Redeye updates on Invisio ahead of its Q1-results (due 7 May) where we expect a strong order intake ...
Redeye updates its estimates and valuation following ADDvise releasing its Q1 2024 report, which fea...
Redeye updates its estimates and valuation following Vitec releasing its Q1 2024 report.
Including Brage acquisition in our estimates Løvmeis exploration well in Q3'24 - the next big event ...
Q1 weaker than expected... ...but outlook remains bright Low valuation and leverage on market, lower...
Plejds nettoomsättning för det fjärde kvartalet 2023 uppgick till 159,0 MSEK (121,3), en ökning med ...
Arctic Blue Beverages AB (”Arctic Blue Beverages” eller ”Bolaget”) meddelade den 18 april 2024 att B...
Redeye presents its preview of Sedana Medical’s Q1 2024 report, due on April 25.
Redeye revisits its market share assumptions for BONESUPPORT’s extremities business.
